Disease Information

General Information of the Disease (ID: DIS00197)

• Name: Dermatofibrosarcoma protuberans
• ICD: ICD-11: 2B53

Type(s) of Resistant Mechanism of This Disease

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Imatinib

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Caspase recruitment domain family member 10 (CARD10) [1]

• Resistant Disease: Dermatofibrosarcoma protuberans [ICD-11: 2B53.0]
• Molecule Alteration: Missense mutation; chr22:37891880C>G+chr22:37891912C>G
• Resistant Drug: Imatinib
• Experimental Note: Identified from the Human Clinical Data
• Cell Pathway Regulation: NF-kappaB signaling pathway; Inhibition; hsa04064
• In Vitro Model: Dermatofibrosarcoma protuberans tissue; .
• Experiment for Molecule Alteration: Sequencing assay
• Mechanism Description: This finding includes mutations in the CARD10, PPP1R39, SAFB2, and STARD9 genes. CARD10 is associated with the activation of the NK-kB signaling pathway and is known to have clinical implications in gastric cancer, colon cancer, and non-small cell lung cance. A potential role for changes in the PPP1R39 gene has also been suggested in the development of human cancers. Further, the SAFB2 gene product is involved in a variety of cellular process, such as cell growth, apoptosis, and stress response and is associated with breast tumorigenesis. In a recent in vitro study, the STARD9 gene product was shown to be associated with mitotic microtubule formation and cell division and might be a potential candidate target to extend the reach of cancer therapeutics. Among the studies mentioned above, Crone et al. demonstrated that targeting CARD10 by microRNA-146a inhibited NF-kB signaling pathway activation in gastric cancer cell lines via reduction of tumor-promoting cytokines and growth factors including PDGFRB. This study showed the possible association between CARD10 inhibition and decreased level of PDGFR and also implied CARD10 activating mutation may be one of the possible resistance mechanism to PBGFR inhibition by imatinib in DFSP.

Key Molecule: ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 (ACAP2) [1]

• Resistant Disease: Dermatofibrosarcoma protuberans [ICD-11: 2B53.0]
• Molecule Alteration: Missense mutation; chr3:195041480C>T
• Resistant Drug: Imatinib
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Dermatofibrosarcoma protuberans tissue; .
• Experiment for Molecule Alteration: Sequencing assay
• Mechanism Description: This finding includes mutations in the CARD10, PPP1R39, SAFB2, and STARD9 genes. CARD10 is associated with the activation of the NK-kB signaling pathway and is known to have clinical implications in gastric cancer, colon cancer, and non-small cell lung cance. A potential role for changes in the PPP1R39 gene has also been suggested in the development of human cancers. Further, the SAFB2 gene product is involved in a variety of cellular process, such as cell growth, apoptosis, and stress response and is associated with breast tumorigenesis. In a recent in vitro study, the STARD9 gene product was shown to be associated with mitotic microtubule formation and cell division and might be a potential candidate target to extend the reach of cancer therapeutics. Among the studies mentioned above, Crone et al. demonstrated that targeting CARD10 by microRNA-146a inhibited NF-kB signaling pathway activation in gastric cancer cell lines via reduction of tumor-promoting cytokines and growth factors including PDGFRB. This study showed the possible association between CARD10 inhibition and decreased level of PDGFR and also implied CARD10 activating mutation may be one of the possible resistance mechanism to PBGFR inhibition by imatinib in DFSP.

Key Molecule: Katanin interacting protein (KATNIP) [1]

• Resistant Disease: Dermatofibrosarcoma protuberans [ICD-11: 2B53.0]
• Molecule Alteration: Missense mutation; chr16:27788348G>T
• Resistant Drug: Imatinib
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Dermatofibrosarcoma protuberans tissue; .
• Experiment for Molecule Alteration: Sequencing assay
• Mechanism Description: This finding includes mutations in the CARD10, PPP1R39, SAFB2, and STARD9 genes. CARD10 is associated with the activation of the NK-kB signaling pathway and is known to have clinical implications in gastric cancer, colon cancer, and non-small cell lung cance. A potential role for changes in the PPP1R39 gene has also been suggested in the development of human cancers. Further, the SAFB2 gene product is involved in a variety of cellular process, such as cell growth, apoptosis, and stress response and is associated with breast tumorigenesis. In a recent in vitro study, the STARD9 gene product was shown to be associated with mitotic microtubule formation and cell division and might be a potential candidate target to extend the reach of cancer therapeutics. Among the studies mentioned above, Crone et al. demonstrated that targeting CARD10 by microRNA-146a inhibited NF-kB signaling pathway activation in gastric cancer cell lines via reduction of tumor-promoting cytokines and growth factors including PDGFRB. This study showed the possible association between CARD10 inhibition and decreased level of PDGFR and also implied CARD10 activating mutation may be one of the possible resistance mechanism to PBGFR inhibition by imatinib in DFSP.

Key Molecule: PAAQR7 (PAAQR7) [1]

• Resistant Disease: Dermatofibrosarcoma protuberans [ICD-11: 2B53.0]
• Molecule Alteration: Missense mutation; chr1:26190151G>T
• Resistant Drug: Imatinib
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Dermatofibrosarcoma protuberans tissue; .
• Experiment for Molecule Alteration: Sequencing assay
• Mechanism Description: This finding includes mutations in the CARD10, PPP1R39, SAFB2, and STARD9 genes. CARD10 is associated with the activation of the NK-kB signaling pathway and is known to have clinical implications in gastric cancer, colon cancer, and non-small cell lung cance. A potential role for changes in the PPP1R39 gene has also been suggested in the development of human cancers. Further, the SAFB2 gene product is involved in a variety of cellular process, such as cell growth, apoptosis, and stress response and is associated with breast tumorigenesis. In a recent in vitro study, the STARD9 gene product was shown to be associated with mitotic microtubule formation and cell division and might be a potential candidate target to extend the reach of cancer therapeutics. Among the studies mentioned above, Crone et al. demonstrated that targeting CARD10 by microRNA-146a inhibited NF-kB signaling pathway activation in gastric cancer cell lines via reduction of tumor-promoting cytokines and growth factors including PDGFRB. This study showed the possible association between CARD10 inhibition and decreased level of PDGFR and also implied CARD10 activating mutation may be one of the possible resistance mechanism to PBGFR inhibition by imatinib in DFSP.

Key Molecule: SH3 domain containing ring finger 2 (SH3RF2) [1]

• Resistant Disease: Dermatofibrosarcoma protuberans [ICD-11: 2B53.0]
• Molecule Alteration: Missense mutation; chr5:145435750G>A
• Resistant Drug: Imatinib
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Dermatofibrosarcoma protuberans tissue; .
• Experiment for Molecule Alteration: Sequencing assay
• Mechanism Description: This finding includes mutations in the CARD10, PPP1R39, SAFB2, and STARD9 genes. CARD10 is associated with the activation of the NK-kB signaling pathway and is known to have clinical implications in gastric cancer, colon cancer, and non-small cell lung cance. A potential role for changes in the PPP1R39 gene has also been suggested in the development of human cancers. Further, the SAFB2 gene product is involved in a variety of cellular process, such as cell growth, apoptosis, and stress response and is associated with breast tumorigenesis. In a recent in vitro study, the STARD9 gene product was shown to be associated with mitotic microtubule formation and cell division and might be a potential candidate target to extend the reach of cancer therapeutics. Among the studies mentioned above, Crone et al. demonstrated that targeting CARD10 by microRNA-146a inhibited NF-kB signaling pathway activation in gastric cancer cell lines via reduction of tumor-promoting cytokines and growth factors including PDGFRB. This study showed the possible association between CARD10 inhibition and decreased level of PDGFR and also implied CARD10 activating mutation may be one of the possible resistance mechanism to PBGFR inhibition by imatinib in DFSP.

Key Molecule: Scaffold attachment factor B2 (SAFB2) [1]

• Resistant Disease: Dermatofibrosarcoma protuberans [ICD-11: 2B53.0]
• Molecule Alteration: Missense mutation; chr19:5587776C>T
• Resistant Drug: Imatinib
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Dermatofibrosarcoma protuberans tissue; .
• Experiment for Molecule Alteration: Sequencing assay
• Mechanism Description: This finding includes mutations in the CARD10, PPP1R39, SAFB2, and STARD9 genes. CARD10 is associated with the activation of the NK-kB signaling pathway and is known to have clinical implications in gastric cancer, colon cancer, and non-small cell lung cance. A potential role for changes in the PPP1R39 gene has also been suggested in the development of human cancers. Further, the SAFB2 gene product is involved in a variety of cellular process, such as cell growth, apoptosis, and stress response and is associated with breast tumorigenesis. In a recent in vitro study, the STARD9 gene product was shown to be associated with mitotic microtubule formation and cell division and might be a potential candidate target to extend the reach of cancer therapeutics. Among the studies mentioned above, Crone et al. demonstrated that targeting CARD10 by microRNA-146a inhibited NF-kB signaling pathway activation in gastric cancer cell lines via reduction of tumor-promoting cytokines and growth factors including PDGFRB. This study showed the possible association between CARD10 inhibition and decreased level of PDGFR and also implied CARD10 activating mutation may be one of the possible resistance mechanism to PBGFR inhibition by imatinib in DFSP.

Key Molecule: StAR related lipid transfer domain containing 9 (STARD9) [1]

• Resistant Disease: Dermatofibrosarcoma protuberans [ICD-11: 2B53.0]
• Molecule Alteration: Missense mutation; chr15:42984506G>A
• Resistant Drug: Imatinib
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Dermatofibrosarcoma protuberans tissue; .
• Experiment for Molecule Alteration: Sequencing assay
• Mechanism Description: This finding includes mutations in the CARD10, PPP1R39, SAFB2, and STARD9 genes. CARD10 is associated with the activation of the NK-kB signaling pathway and is known to have clinical implications in gastric cancer, colon cancer, and non-small cell lung cance. A potential role for changes in the PPP1R39 gene has also been suggested in the development of human cancers. Further, the SAFB2 gene product is involved in a variety of cellular process, such as cell growth, apoptosis, and stress response and is associated with breast tumorigenesis. In a recent in vitro study, the STARD9 gene product was shown to be associated with mitotic microtubule formation and cell division and might be a potential candidate target to extend the reach of cancer therapeutics. Among the studies mentioned above, Crone et al. demonstrated that targeting CARD10 by microRNA-146a inhibited NF-kB signaling pathway activation in gastric cancer cell lines via reduction of tumor-promoting cytokines and growth factors including PDGFRB. This study showed the possible association between CARD10 inhibition and decreased level of PDGFR and also implied CARD10 activating mutation may be one of the possible resistance mechanism to PBGFR inhibition by imatinib in DFSP.

Key Molecule: Zinc finger FYVE-type containing 9 (ZFYVE9) [1]

• Resistant Disease: Dermatofibrosarcoma protuberans [ICD-11: 2B53.0]
• Molecule Alteration: Missense mutation; chr1:52704185G>T
• Resistant Drug: Imatinib
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Dermatofibrosarcoma protuberans tissue; .
• Experiment for Molecule Alteration: Sequencing assay
• Mechanism Description: This finding includes mutations in the CARD10, PPP1R39, SAFB2, and STARD9 genes. CARD10 is associated with the activation of the NK-kB signaling pathway and is known to have clinical implications in gastric cancer, colon cancer, and non-small cell lung cance. A potential role for changes in the PPP1R39 gene has also been suggested in the development of human cancers. Further, the SAFB2 gene product is involved in a variety of cellular process, such as cell growth, apoptosis, and stress response and is associated with breast tumorigenesis. In a recent in vitro study, the STARD9 gene product was shown to be associated with mitotic microtubule formation and cell division and might be a potential candidate target to extend the reach of cancer therapeutics. Among the studies mentioned above, Crone et al. demonstrated that targeting CARD10 by microRNA-146a inhibited NF-kB signaling pathway activation in gastric cancer cell lines via reduction of tumor-promoting cytokines and growth factors including PDGFRB. This study showed the possible association between CARD10 inhibition and decreased level of PDGFR and also implied CARD10 activating mutation may be one of the possible resistance mechanism to PBGFR inhibition by imatinib in DFSP.

References

• Ref 1: Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing .PLoS One. 2013 Jul 29;8(7):e69752. doi: 10.1371/journal.pone.0069752. Print 2013. 10.1371/journal.pone.0069752